Signed supplier agreement with NutraQ AS for 2016

(Tromsø, 19th January 2016) Biotec BetaGlucans AS, a fully owned subsidiary of Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC), announces that it has signed a non-exclusive supplier agreement for production and delivery of betaglucans to the nutrition segment with NutraQ AS for one year from January 1st 2016 to December 31st 2016.

 We are pleased to have signed this supply agreement with our partner NutraQ. The contract value is dependent on NutraQ’s commercial activities says Svein Lien, Chief Executive Officer of … continue reading »

Invitation to Capital Markets Day 11 February 2016

(Tromsø, 18 December 2015) Biotec Pharmacon ASA (OSE:Biotec) will host a Capital Markets Day (CMD) on Thursday, 11 February 2016 following the Q4 presentation.

Time: 08.30 – 11.00

Location: Hotel Continental, Stortingsgaten 24/26, Oslo

Speakers will be:
Svein Lien (CEO),
Jethro Holter (MD, ArcticZymes),
Stuart Devine (VP Marketing, Woulgan®) and
Rolf Engstad (CSO)

Breakfast will be served prior to the presentations. For practical reasons, investors, analysts and journalists coming to the event are encouraged to register via email to *protected email* by 4 February 2016.

The Q4 and the … continue reading »

Enters into Nordic distribution agreement for Woulgan® with Navamedic

(Tromsø, 4 December 2015) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) has entered into a distribution agreement for Woulgan® with Nordic distributor Navamedic ASA (Navamedic).

– Biotec is pleased to announce Navamedic as our Nordic partner for the distribution of Woulgan®. The agreement is in line with our strategy of signing up strong regional business partners for the distribution of Woulgan®. Navamedic has a solid position in the Nordic market and the ability to give Woulgan® the focus needed to make … continue reading »

New online Q&A section

Biotec Pharmacon has a committed and active shareholder community and some shareholders are frequently in direct contact with the management. An open and proactive approach towards investor relations are one of the company’s key priorities.

In order to give information to all shareholders, Biotec Pharmacon will expand its IR services with a routine where questions asked from shareholders where the answers may be of general interest, will be published on a dedicated Q&A section on All questions will be … continue reading »

Presentation Q3 2015 results

Biotec Pharmacon presents its report for the third quarter 2015 on Tuesday,  3rd November. The presentation will be given by CEO Svein Lien.

The presentation starts at 08:30 am and will be in Norwegian.

Venue: Hotell Continental, Stortingsgata 24, Oslo.

The presentation can also be followed as a live webcast from Hegnar TV, and it will be possible to post questions through the webcast console at the end of the presentation.

The interim report for the third quarter 2015 will be available on and … continue reading »

Hiring of Vice President Marketing Woulgan

Biotec Betaglucans is pleased to announce that Stuart Devine is hired as Vice President Marketing Woulgan.He will join the company in December 2015. Stuart Devine has more than 20 years’ sales and marketing experience in global healthcare corporations including Kimberly-Clark Health Care and CR Bard. Stuart Devine joins us from Smith & Nephew where he was Senior Director Global Marketing in the Advanced Wound Care Division. His position will be located in the UK.

-Stuart’s strong commercial track record together with his global … continue reading »

Lyst til å jobbe deltid med sosiale medier?

Biotec Pharmacon AS har skapt revolusjonerende behandlingsteknologi. Vårt sårbehandlingsprodukt Woulgan® er klart for markedet, og vi ønsker å nå ut med vårt budskap til flest mulig – både pasienter og brukere. Woulgan® markedsføres i dag i ulike kanaler. Vi ønsker nå også å profilere produktet på sosiale medier. Der trenger vi din hjelp. Vi søker etter en engasjert og kreativ person, med inngående kunnskaper om sosiale medier. Erfaring fra profesjonell bruk er en fordel.

Vi har ikke tidligere benyttet sosiale medier … continue reading »